Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25242024 | 0.99 | FOLH1 (0.37) | FOLH1HDAC8HDAC1HDAC2HDAC7 | |
| SCHEMBL25242026 | 0.99 | FOLH1 (0.37) | FOLH1HDAC8HDAC1HDAC2HDAC7 | |
| SCHEMBL31681443 | 0.93 | SIRT1 (0.37) | SIRT1SIRT2 | |
| SCHEMBL25245450 | 0.92 | FOLH1 (0.35) | FOLH1HDAC8HDAC1HDAC2HDAC7 | |
| SCHEMBL27189832 | 0.89 | HDAC8 (0.34) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL27190126 | 0.89 | HDAC8 (0.34) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL26066853 | 0.89 | HDAC8 (0.39) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL26066857 | 0.89 | HDAC8 (0.39) | HDAC8HDAC1HDAC2HDAC7HDAC3 | |
| SCHEMBL21118854 | 0.87 | FOLH1 (0.36) | FOLH1HDAC1HDAC7 | |
| SCHEMBL22388632 | 0.83 | FOLH1 (0.37) | FOLH1HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541047-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | IMMUNOMEDICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2021143741-A1 | TARGETING POLYPEPTIDE-DRUG CONJUGATE AND USE THEREOF | 北京海步医药科技有限公司 | 2021-07-22 | — | — | WO | disclosed |
| US-11020489-B2 | Immunoconjugates with an intracellularly-cleavable linkage | IMMUNOMEDICS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200316054-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-20200276325-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | IMMUNOMEDICS, INC. | 2020-09-03 | — | — | US | disclosed |
| US-10206918-B2 | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | IMMUNOMEDICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180161440-A1 | ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER | JOHNSON MATTHEY PHARMACEUTICAL MATERIALS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20170360770-A1 | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS | IMMUNOMEDICS, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200316054-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | CD74, CD2, CD22 | FOLH1 142/4885HDAC8 1358/4885HDAC1 3175/4885 |
| US-11020489-B2 | Immunoconjugates with an intracellularly-cleavable linkage | CD47, CD44, DNPEP | FOLH1 5/4885HDAC8 1243/4885HDAC1 2407/4885 |
| US-20180161440-A1 | ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER | CLTA, CLTC, FCGR2A | FOLH1 1919/4885HDAC8 2200/4885HDAC1 3821/4885 |
| US-20170360770-A1 | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS | CD74, HLA-DRB1, MCL1 | FOLH1 1827/4885HDAC8 1259/4885HDAC1 1387/4885 |
| US-20200276325-A1 | Immunoconjugates with an Intracellularly-Cleavable Linkage | CD47, CD44, DNPEP | FOLH1 5/4885HDAC8 1243/4885HDAC1 2407/4885 |
| US-11541047-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | CD74, CD2, CD22 | FOLH1 142/4885HDAC8 1358/4885HDAC1 3175/4885 |
| US-10206918-B2 | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | CD74, HLA-DRB1, MCL1 | FOLH1 1923/4885HDAC8 2602/4885HDAC1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.